Please login to the form below

Not currently logged in
Email:
Password:

cost

This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.

EMA clears BMS’ oral multiple sclerosis drug Zeposia

EMA clears BMS’ oral multiple sclerosis drug Zeposia

There are other entrenched oral therapies to contend with, notably Biogen’s Tecfidera (dimethyl fumarate) which also has low-cost generics on the horizon that could exert downward pressure on oral

Latest news

  • NICE approves Roche’s Tecentriq in TNBC after revising deal NICE approves Roche’s Tecentriq in TNBC after revising deal

    Draft guidance from NICE, released late last year, did not recommend the use of Tecentriq (atezolizumab) after determining that the drug was not cost-effective in the TNBC setting, even as ... According to the cost-effectiveness agency, out of the

  • Generation Z Generation Z

    As we move forward, how we reconcile the need and benefit for all stakeholders of keeping the best talent in our sector, against the need for cost reduction, is something that

  • Innovation in the time of coronavirus Innovation in the time of coronavirus

    A Distancer currently costs £4 or $5.50 (plus any applicable VAT).

  • Key emerging trends in digital health Key emerging trends in digital health

    A major issue facing the pharmaceutical industry is the growing costs of research and development of new drugs, with clinical trials shouldering much of that expense. ... Not only can a home-based clinical trial possibly reduce the costs of clinical

  • Current and future trends for developing digital medical communications Current and future trends for developing digital medical communications

    For example, content management within these platforms is now much more straightforward, with pieces of content in multiple formats being quickly (and therefore cost-effectively) dropped into pre-prepared spaces. ... we might expect the number of

More from news
Approximately 9 fully matching, plus 2,896 partially matching documents found.

Latest Intelligence

  • The big issue The big issue

    Making pins involves many steps and when workers specialise on one step, then pass it on to the next specialist, they produce more pins, at less cost, than their solitary, generalist ... They value subordinates who understand and support organisational

  • Risks, reforms and rewards: the evolving Russian healthcare market Risks, reforms and rewards: the evolving Russian healthcare market

    State spending on pharmaceuticals, which includes medicines bought by hospitals, ‘high cost drugs’ under the ICD programme, drugs on the essential drugs list and those purchased by regional authorities, was flat

  • Biopharma and orphan drugs Biopharma and orphan drugs

    According to a 2019 study, for example, the mean orphan drug cost per patient of the top 100 US orphan drugs was almost 4.5 times greater than the non-orphan ... drug cost in 2018.

  • Industry needs an aligned position on the future of the EU OMP Regulation Industry needs an aligned position on the future of the EU OMP Regulation

    Increasing transparency of R&D costs is being considered, to enable better analysis.

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    Specifically, M&A can be the path to larger pharma companies bolstering their portfolios with more innovative products, without undertaking the high cost and risk of R&D. ... This trend is unlikely to stop anytime soon, not least as R&D is of course

More from intelligence
Approximately 2 fully matching, plus 491 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 372 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics